Suzanne James, NP
Family · Kansas City, MONPI 1487187316
Payments from drug & device makers
Across 139 payments — averaging $23.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- OPKO Pharmaceuticals, LLC$1K
- Amgen$550
- AstraZeneca$332
- Vifor Pharma, Inc.$297
- Boehringer Ingelheim$234
- Akebia Therapeutics Inc$182
- plus $667 from 12 others
What the payments were for
- Food & beverage$3,323100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| OPKO Pharmaceuticals, LLC | 75 | $1,061 |
| Amgen(2 entities) | 9 | $550 |
| AstraZeneca | 8 | $332 |
| Vifor Pharma, Inc. | 5 | $297 |
| Boehringer Ingelheim | 10 | $234 |
| Akebia Therapeutics Inc | 3 | $182 |
| Calliditas Therapeutics US Inc. | 6 | $128 |
| Daiichi Sankyo Inc. | 1 | $111 |
| Travere Therapeutics, Inc. | 9 | $90 |
| Ardelyx, Inc. | 1 | $85 |
| Nxstage Medical, Inc. | 2 | $83 |
| Bayer | 3 | $47 |
| Fresenius USA Marketing, Inc. | 2 | $34 |
| Novartis | 1 | $27 |
| Apellis Pharmaceuticals, Inc. | 1 | $20 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
| GSK | 1 | $14 |
| Mallinckrodt Hospital Products Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRYSTEXXA$233
- JARDIANCE$114
- Tavneos$113
- INJECTAFER$111
How this compares
$3,323 in reported general payments places this provider in the 85th percentile of 3,812 family providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 104 | $73,409 |
| RayaldeeCalcifediol | 37 | $62,620 |
| FarxigaDapagliflozin Propanediol | 73 | $53,688 |
| VelphoroSucroferric Oxyhydroxide | 25 | $46,253 |
| VeltassaPatiromer Calcium Sorbitex | 40 | $40,206 |
| ProsolParenteral Amino Acid 20% No.1 | 107 | $28,585 |
| LokelmaSodium Zirconium Cyclosilicate | 41 | $24,918 |
| Sevelamer Carbonate | 56 | $12,544 |
| Calcitriol | 127 | $2,454 |
| Torsemide | 69 | $1,055 |
| Losartan Potassium | 121 | $901 |
| Allopurinol | 77 | $594 |
| Amlodipine Besylate | 143 | $581 |
| Calcium Acetate | 18 | $483 |
| Carvedilol | 94 | $473 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $332 | $78,606114 claims |
| Boehringer IngelheimJardiance | $234 | $73,409104 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $1,061 | $62,62037 claims |
| Fresenius USA Marketing, Inc.Velphoro | $34 | $46,25325 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $15 | $45133 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,812 family providers in Missouri.
Other family in Kansas City
- Shayla SandersKansas City$306K
- Oyinkan PennyKansas City$36K
- Goldie BenzKansas City$27K
- Lucy Carter ReardonKansas City$25K
- Lyla MastersKansas City$22K
- Donna McCurryKansas City$20K
- Mary Zahau LoehnerKansas City$20K
- Cherie NydeggerKansas City$17K
- Charity SlaytonKansas City$17K
- Samantha IrwinKansas City$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.